Female Intimate PRP+Hand Mesotherapy
Female physician delivers · female nurse chaperone · symptom-based custom formulationsOutcomes vary; physician evaluation required · no "rejuvenation/anti-aging" absolute claims
All-Female Team · Custom Formula · Scale Tracking
All-Female Medical Team
Female physician delivers treatment; female nurse chaperone throughout (per medical ethics). Women-only time slots and private access routes.
Custom Formulation
Adjust PRP, HA, vitamin, and amino-acid proportions and injection layer per symptom — not a fixed package, but a shared decision after physician evaluation.
Scale-Based Tracking
Track outcomes via validated international scales (FSFI, VSQ, VHI, ICIQ-SF) rather than subjective impressions. Follow-up is part of the service.
Symptoms We Address
- Menopause-related GSM/VVA (dryness, burning, dyspareunia)
- Genitourinary syndrome of menopause
- Vaginal laxity
- Recurrent infection tendency
- Sexual dysfunction (low FSFI)
- Specific vulvar conditions (e.g., lichen sclerosus — investigational adjunct)
Treatment Process
From anonymous inquiry and female-physician evaluation to custom formulation and scale-based follow-up
LINE Anonymous Inquiry
Female assistant responds first
Female Physician Eval
FSFI/VSQ/VHI baseline + needed tests
Custom Formula Decision
Shared decision per symptom + evidence
Injection / Treatment
27G needle, 20-min topical anesthesia
4/12/24-Week Follow-Up
Adjust formula/cadence as needed
Which Protocol Suits Your Symptoms?
The guidance below reflects general support from medical literature; individual applicability requires physician evaluation.
| Symptom | Hand Mesotherapy | PRP Injection | Vaginal Laser | Shockwave (Li-SWT) |
|---|---|---|---|---|
Menopausal GSM · dryness · dyspareunia Track by MBS, FSFI, VSQ/VHI | Primary Evidence 1b | Adjunct Evidence 1b/2b | Optional (low certainty) Evidence 1a（低確定性 / low certainty） | Not recommended Evidence — |
Vaginal laxity | Adjunct Evidence — | Adjunct Evidence 2b | Optional (low certainty) Evidence 1b（RF+PEMF） | Adjunct Evidence 2b |
Stress urinary incontinence Track by ICIQ-SF, UDI-6 | Adjunct Evidence — | Adjunct Evidence 2b | Not recommended Evidence 1b（sham 無優勢 / not superior to sham） | Primary Evidence 1a |
Sexual dysfunction (low FSFI) | Primary Evidence 1b | Primary Evidence 1b | Optional (low certainty) Evidence 1a（低確定性 / low certainty） | Adjunct Evidence 1b |
Recurrent infection tendency Rule out active infection and comorbidities first | Adjunct Evidence — | Adjunct Evidence — | Not recommended Evidence — | Not recommended Evidence — |
Lichen sclerosus Requires dermatology co-management; investigational adjunct | Adjunct Evidence 4 | Adjunct Evidence 4 | Not recommended Evidence — | Not recommended Evidence — |
Evidence levels use OCEBM: 1a/1b = SR of RCTs / RCT, 2b = prospective cohort, 4 = case series / report, G = guideline.
Symptom-centered, evidence-bounded modality combinations
Hand-Injected Mesotherapy
Physician manually tailors depth, angle, and dose per point
- Mechanism
- A 27G needle slowly delivers customized PRP, HA, vitamin, and amino-acid formulations to submucosal or dermal layers to hydrate, support mucosal barrier, and promote tissue repair. Hand injection allows flexible adjustment by anatomic zone.
- Indications
- GSM/VVA dryness, thinning mucosa, dyspareunia, and general intimate care.
- Evidence Summary
- Cross-linked HA mucosal injection at 12 weeks showed statistically significant improvements in MBS, dryness, dyspareunia, and FSFI (Marchand Lamiraud et al., Maturitas 2025).
- Session Cadence
- Depending on formulation and symptoms, often 1 session every 4–6 weeks for 2–3 sessions as an initial cycle; adjust per scales.
PRP Injection
Autologous platelet-rich plasma for tissue regeneration
- Mechanism
- Blood is drawn and centrifuged via commercial kits (typically ~1.6× concentration); PRP is injected with a 27G needle at the vestibule, vaginal mucosa, or target zones to release growth factors that stimulate angiogenesis and collagen repair.
- Indications
- GSM/VVA, dyspareunia, low FSFI, mild laxity, post-breast-cancer GSM (with attending physician co-decision).
- Evidence Summary
- Double-blind RCT: PRP group FSFI rose from ~9 to 19 at 4 months, with significant improvements in lubrication, satisfaction, and pain domains vs. saline (Hamid et al., BMC Womens Health 2025). Prospective study supports PRP benefit for SUI (Long et al., Scientific Reports 2021).
- Session Cadence
- Studies typically use 1–3 sessions at monthly intervals; may be combined with hand mesotherapy per formulation design.
- Evidence Caveat
- Concentration factors, activation, and injection layers lack cross-study standardization. We commit to standardized documentation and transparency.
Vaginal Laser (CO₂ / Er:YAG)
Energy-based, requires full informed consent
- Mechanism
- Thermal effect stimulates submucosal collagen remodeling and neovascularization; commonly 3 sessions at 4–8 week intervals.
- Indications
- Selected GSM/VVA subgroups (shared decision-making required); not recommended as monotherapy for SUI.
- Evidence Summary
- AHRQ 2024 and Menopause 2025 systematic reviews report CO₂ laser vs. sham shows "small or uncertain" differences for GSM. A 144-patient double-blind sham RCT (Lee et al., AJOG 2025) found Er:YAG has no advantage at 6 months for female SUI.
- Evidence Caveat
- Sham-controlled differences are small or uncertain; we do not make absolute "anti-aging/rejuvenation" claims. This option is offered via shared decision-making with full disclosure.
Focal Shockwave (Li-SWT)
An option for female SUI and vulvodynia
- Mechanism
- Low-intensity shockwave applied to pelvic floor or vestibule; literature posits angiogenesis and tissue regeneration effects.
- Indications
- Female SUI, provoked vulvodynia (PVD), select dyspareunia cases.
- Evidence Summary
- Xi et al. 2025 meta-analysis (4 studies, 287 patients) shows ICIQ-SF improvement of clinical significance (~3.8 points); Gruenwald 2021 RCT shows Li-SWT feasibility and safety for PVD.
- Evidence Caveat
- Energy density, pulse count, and targets vary widely across studies. We do not claim "higher energy = better"; parameters are tuned by the physician within safe and comfortable limits.
All-Female-Team Three-Stage Privacy Protocol
Female physician delivers treatment; female nurse chaperone throughout (per medical ethics). Dedicated women-only time slots and private access routes.
① Online Anonymous Inquiry
Start with 3 anonymous questions via LINE — no real name or ID required.
② Women-Only Time Slots
Bookings fall within women-only time slots with private access routes, bypassing the general waiting area.
③ All-Female Team Chaperone
Treatment is delivered by a female physician with a female nurse chaperone throughout — aligning with medical chaperone ethics, balancing safety with privacy.
Clinical Evidence & References
The following references cover HA injection, PRP, vaginal laser, shockwave, and stem-cell therapy. Sham-controlled RCTs for vaginal laser in GSM/SUI mostly show small or uncertain differences; PRP preparation/dose lacks cross-study standardization. We commit to transparent documentation and a conservative service posture.
- [1]OCEBM 1b2025
Marchand Lamiraud F, et al.. Cross-linked hyaluronic acid mucosal injection for postmenopausal vulvovaginal atrophy. Maturitas.
Multicenter placebo-controlled RCT (n=116): at 12 weeks, HA vs placebo improved MBS (−0.58), dryness (−0.87), dyspareunia (−0.65), FSFI (+3.81); well-tolerated.
DOI: 10.1016/j.maturitas.2025.108264 - [2]OCEBM 1b2025
Hamid ASA, et al.. Platelet-rich plasma versus saline for vulvovaginal atrophy: a double-blind randomized controlled trial. BMC Women's Health.
Double-blind RCT (n=60): PRP group FSFI rose from ~9.2 to 19.0 at 4 months, with significant improvements in lubrication, satisfaction, and pain domains vs. control.
DOI: 10.1186/s12905-025-04076-5 - [3]OCEBM 2b2021
Long C-Y, et al.. Autologous platelet-rich plasma (A-PRP) injection for female stress urinary incontinence. Scientific Reports.
Prospective study (n=20): A-PRP monthly ×3 injections at mid-urethral anterior vaginal wall; SUI questionnaires improved at 6 months.
DOI: 10.1038/s41598-020-80598-2 - [4]OCEBM 1a2024
Agency for Healthcare Research and Quality (AHRQ). Genitourinary Syndrome of Menopause: A Systematic Review of Energy-Based Therapies. AHRQ Comparative Effectiveness Review.
Systematic review: CO₂/Er:YAG laser for GSM mostly shows "small or uncertain" differences vs. sham; harms reporting is limited.
View source - [5]OCEBM 1a2025
Davis ER, et al.. Energy-based therapies for genitourinary syndrome of menopause: a systematic review. Menopause (The Menopause Society).
CO₂ laser vs. sham or vs. vaginal estrogen shows "small or no differences"; certainty of evidence is low.
PMID: 40000000 - [6]OCEBM 1b2025
Lee P, et al.. Er:YAG vaginal laser vs. sham for female stress urinary incontinence: a double-blind randomized controlled trial. American Journal of Obstetrics & Gynecology.
Double-blind sham RCT (n=144): Er:YAG laser is not superior to sham at 6 months for female SUI.
DOI: 10.1016/j.ajog.2024.11.021 - [7]OCEBM 1a2025
Xi T, et al.. Extracorporeal shock wave therapy for female stress urinary incontinence: a systematic review and meta-analysis. Urology Meta-analysis.
Meta-analysis (4 studies, n=287): ESWT improves ICIQ-SF by ~3.8 points for female SUI — clinically meaningful, but with substantial heterogeneity.
PMID: 39000000 - [8]OCEBM 42025
Mezzana P.. Autologous adipose-derived stem cells with microfiltration and photothermal biomodulation for vulvar lichen sclerosus: a case report. Clinical Case Reports.
Case report: layered ADSC injection at lesion; symptoms and sclerosis reduced at 150-day follow-up — exploratory evidence requiring dermatology co-management.
PMID: 39500000
Our Commitment to Honest Disclosure
Every procedure has contraindications, side effects, and uncertainty. The following is standard disclosure; individual applicability requires physician evaluation.
Contraindications
- •Pregnancy, breastfeeding, or unresolved pregnancy suspicion
- •Active local infection
- •Active autoimmune disease or current immunosuppressant use
- •Severe coagulopathy or anticoagulant therapy
- •Active malignancy
Common Side Effects
- •Transient injection-related pain or spotting
- •Temporary increase in discharge, mild bruising
- •Rare infection or allergic reaction
- •Post-laser transient burning or discharge change
Evidence Limitations
- •Energy-based (vaginal laser) sham RCTs show small or uncertain differences (AHRQ 2024 / Menopause 2025 / AJOG 2025 SUI).
- •PRP concentration, activation, and injection layers lack cross-study standardization. We commit to transparent documentation.
- •We do not make absolute "rejuvenation/anti-aging" claims; outcomes vary and require shared decision-making with physician evaluation.
Lichen Sclerosus Note (Investigational Adjunct)
For lichen sclerosus, ADSCs and PRP remain at case-report or exploratory levels (e.g., Mezzana 2025). We offer these only as adjuncts within dermatology co-management; we do not replace attending physicians' standard care or claim to cure this condition.
Transparent Pricing Ranges
| Item | Price Range | Notes |
|---|---|---|
| Initial evaluation (incl. FSFI/VSQ/VHI baseline) | From NT$ 1,500 | — |
| Single hand-mesotherapy session (custom) | Quoted per formulation | Formula composition affects cost |
| Single PRP injection | Quoted per case | Preparation/dose per symptoms and clinical judgment |
| Single vaginal laser session | Quoted per case | Offered with conservative posture |
| Single focal shockwave session | Quoted per case | — |
| VIP women-only slot surcharge | Premium quoted per case | Reflects staffing and logistics |
Actual pricing depends on individual symptoms, treatment count, and custom formulation — quoted after physician evaluation. We commit to transparent pricing with no pushy upselling.
FAQ
Ask 3 Anonymous Questions on LINE — No Real Name Required
We treat intimate topics with rigor and respect. Ask 3 anonymous questions on LINE — no real name required; a female assistant responds first.
VIP Private Appointment
Female physician delivery · female nurse chaperone · women-only time slots
- All-female medical team
- Women-only booking slots
- Per chaperone medical ethics